KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
KBIO was delisted on the 16th of December, 2015.
35 hedge funds and large institutions have $25.1M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 11 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
19% less funds holding
Funds holding: 43 → 35 (-8)
37% less capital invested
Capital invested by funds: $39.8M → $25.1M (-$14.6M)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$776K |
| 2 |
DM
Deerfield Management
New York
|
+$497K |
| 3 |
SIM
SSI Investment Management
Los Angeles,
California
|
+$322K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$109K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.08M |
| 2 |
WSA
Wall Street Associates
Lajolla,
California
|
-$1.39M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$730K |
| 4 |
Renaissance Technologies
New York
|
-$204K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$174K |
KBIO Hedge Fund Activity: Q3 2014 in Review
35 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q3 2014, worth a combined $25.1M — down 37% from $39.8M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of KBIO and 3 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 10 added.
The largest buyer was UBS AM, adding an estimated $776K. The largest seller was Great Point Partners, exiting entirely with an estimated $2.08M sold.
- 35 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q3 2014, down from 43 in Q2 2014.
- Funds reported $25.1M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q3 2014, down 37% quarter-over-quarter.
- 3 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q3 2014 and 11 closed out, a net change of -8 holders.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q3 2014 was UBS AM, an estimated $776K added.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q3 2014 was Great Point Partners, an estimated $2.08M sold.
Based on aggregated 13F filings for Q3 2014.